Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
NaaS Wins Bid for Zhejiang Charging Regulation Platform, Empowering Digital Infrastructure
NaaS's successful bid for constructing the Zhejiang Provincial Charging Regulation Platform marks the formation of new qualitative productive forces, driving high-quality development in the region.
Feb 26, 2024 09:23 PM
Beijing Pilots The DRG External Payment Mode
DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.
Jul 16, 2022 12:12 AM
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM
Temu Unleashed: A Journey of Skepticism, Revelation, and the Quest to Redefine E-commerce
Jan 06, 2024 12:16 PM